Retiring NIB chief Mark Fitzgibbon on the two biggest issues facing the private health sector: the brawl between hospitals and insurers, and the future of care.
During his 22 years running private health insurer NIB, chief executive Mark Fitzgibbon has never been one to pull his punches. At his final profit announcement on Monday, he delivered a couple of big calls.
“We’ll all be taking GLP-1 agonists [the class of drug that includes Ozempic, Wegovy and Mounjaro] like we do daily vitamins,” he told Chanticleer.
Loading...
James Thomson is senior Chanticleer columnist based in Melbourne. He was the Companies editor and editor of BRW Magazine. Connect with James on Twitter. Email James at j.thomson@afr.com
